Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autoprobiotic enterococci
- Development stage
- Unknown
- Lead developer
- Institute of Experimental Medicine
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Autoprobiotic enterococci are a personalized live biotherapeutic product (LBP) consisting of indigenous, non-pathogenic strains of *Enterococcus faecium* or *Enterococcus hirae* isolated from a patient's own fecal microbiota. Developed by the Institute of Experimental Medicine in St. Petersburg, Russia, this autologous probiotic therapy is designed to restore intestinal microbiocenosis and reduce postoperative complications in patients with colorectal cancer (CRC). The treatment process involves isolating the patient's specific enterococci strains before surgery, culturing them in a soy-based protein-vitamin-mineral complex (such as SUPRO PLUS 2640 DS), and re-administering them orally in the early postoperative period. The therapy aims to suppress pro-carcinogenic bacteria like *Parvomonas micra* and *Fusobacterium nucleatum*, decrease pro-inflammatory cytokines such as IL-6 and IL-18, and enhance the alpha diversity of the gut microbiome, thereby improving clinical outcomes and reducing inflammation.
- Other names
- autoprobioticsindigenous enterococciautoprobiotic Enterococcus faeciumautoprobiotic Enterococcus hirae
Beyond the preview
Go deeper on autoprobiotic enterococci.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autoprobiotic enterococci.